keyword
https://read.qxmd.com/read/38537184/multiparametric-ultrasound-evaluation-of-liver-fibrosis-steatosis-and-viscosity-in-patients-with-chronic-liver-disease
#1
JOURNAL ARTICLE
Iulia Minciuna, Madalina Taru, Andreea Fodor, Oana Nicoara Farcau, Petra Fischer, Corina Radu, Monica Lupsor-Platon, Horia Stefanescu, Bogdan Procopet
AIMS: This study assessed the effectiveness of three ultrasound-based techniques (2D-SWE.PLUS, Att.PLUS, Vi.PLUS) for non-invasive evaluation of liver fibrosis, steatosis, and inflammation in chronic liver disease (CLD) patients.Materials and methods: Involving 209 consecutive compensated CLD patients, the study compared these ultrasound methods from Aixplorerwith standard Vibration-controlled Transient Elastography (VCTE) and Controlled Attenuation Parameter (CAP) from Fibroscan, alongside non-invasive serological markers...
February 7, 2024: Medical Ultrasonography
https://read.qxmd.com/read/38536569/trimethylamine-n-oxide-a-new-risk-factor-for-non-alcoholic-fatty-liver-disease-changes-the-expression-of-mirna-34a-and-mirna-122-in-the-fatty-liver-cell-model
#2
JOURNAL ARTICLE
Zhila Bahramirad, Mohammad Raman Moloudi, Mohammad Moradzad, Alina Abdollahi, Zakaria Vahabzadeh
Non-alcoholic fatty liver disease is a multifactorial disorder with complicated pathophysiology ranging from simple steatosis to steatohepatitis and liver fibrosis. Trimethylamine-N-oxide (TMAO) production is believed to be correlated with choline deficiency. This study investigated the expression of miRNA-34a, miRNA-122, and miRNA-192 in the fatty liver cell model treated with different concentrations of TMAO. A fatty liver cell model was developed by exposing HepG2 cells to a mixture of palmitate and oleate in a ratio of 1:2 at a final concentration of 1200 μM for 24 h...
March 27, 2024: Biochemical Genetics
https://read.qxmd.com/read/38536042/genetic-variation-in-severe-cystic-fibrosis-liver-disease-is-associated-with-novel-mechanisms-for-disease-pathogenesis
#3
JOURNAL ARTICLE
Jaclyn R Stonebraker, Rhonda G Pace, Paul J Gallins, Hong Dang, Melis A Aksit, Anna V Faino, William W Gordon, Sonya MacParland, Michael J Bamshad, Ronald L Gibson, Garry R Cutting, Peter R Durie, Fred A Wright, Yi-Hui Zhou, Scott M Blackman, Wanda K O'Neal, Simon C Ling, Michael R Knowles
BACKGROUND AND AIMS: It is not known why severe cystic fibrosis (CF) liver disease (CFLD) with portal hypertension occurs in only ~7% of people with CF (pwCF). We aimed to identify genetic modifiers for severe CFLD to improve understanding of disease mechanisms. APPROACH AND RESULTS: Whole genome sequencing was available in 4,082 pwCF with pancreatic insufficiency (n=516 with severe CFLD; n=3,566 without CFLD). We tested ~15.9 million SNPs for association with severe CFLD versus no-CFLD, using pre-modulator clinical phenotypes including: 1) genetic variant (SERPINA1; Z-allele) previously associated with severe CFLD; 2) candidate SNPs (n=205) associated with non-CF liver diseases; 3) genome-wide association study (GWAS) of common/rare SNPs; 4) transcriptome-wide association (TWAS); and 5) gene-level and pathway analyses...
March 27, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://read.qxmd.com/read/38536017/effects-of-empagliflozin-on-liver-fat-in-metabolic-dysfunction-associated-steatotic-liver-disease-patients-without-diabetes-mellitus-a-randomized-double-blind-placebo-controlled-trial
#4
JOURNAL ARTICLE
Ka Shing Cheung, Ho Yu Ng, Rex Wan Hin Hui, Lok Ka Lam, Lung Yi Mak, Yuen Chi Ho, Jing Tong Tan, Esther W Chan, Wai Kay Seto, Man Fung Yuen, Wai K Leung
BACKGROUND AND AIMS: We investigated whether empagliflozin reduces hepatic steatosis in metabolic-dysfunction associated steatotic liver disease (MASLD) patients without diabetes mellitus (DM). APPROACH AND RESULTS: This was an investigator-initiated, double-blind, randomized, placebo-controlled trial recruiting adult subjects from the community. Eligible subjects without DM (fasting plasma glucose <7 mmol/L and HbA1c <6.5%) who had magnetic resonance imaging-proton density fat fraction [MRI-PDFF] ≥5% were randomly allocated to receive empagliflozin 10 mg daily or placebo (1:1 ratio) for 52 weeks (end of treatment, EOT)...
March 27, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://read.qxmd.com/read/38532480/dihydromyricetin-ameliorates-hepatic-steatosis-and-insulin-resistance-via-ampk-pgc-1%C3%AE-and-ppar%C3%AE-mediated-autophagy-pathway
#5
JOURNAL ARTICLE
Yan Yang, Wen Qiu, Jiyuan Xiao, Jie Sun, Xuan Ren, Luxia Jiang
BACKGROUND: Dihydromyricetin (DHM), a flavonoid compound of natural origin, has been identified in high concentrations in ampelopsis grossedentata and has a broad spectrum of biological and pharmacological functions, particularly in regulating glucose and lipid metabolism. The objective of this research was to examine how DHM affected nonalcoholic fatty liver disease (NAFLD) and its underlying mechanisms involved in the progression of NAFLD in a rat model subjected to a high-fat diet (HFD)...
March 26, 2024: Journal of Translational Medicine
https://read.qxmd.com/read/38532322/glp-1-glp-1ras-new-options-for-the-drug-treatment-of-nafld
#6
JOURNAL ARTICLE
Haoran Jiang, Linquan Zang
Non-alcoholic fatty liver disease (NAFLD) has recently emerged as a global public health concern. Currently, the cornerstone of NAFLD treatment is lifestyle modification and, if necessary, weight loss. However, compliance is a challenge, and this approach alone may not be sufficient to halt and treat the more serious disease development, so medication is urgently needed. Nevertheless, no medicines are approved to treat NAFLD. Glucagon-like peptide-1 (GLP-1) is an enteropeptide hormone that inhibits glucagon synthesis, promotes insulin secretion, and delays gastric emptying...
2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38531925/comparative-evaluation-of-non-invasive-tests-for-risk-stratification-for-cause-specific-mortality-in-at-risk-population-of-hepatic-fibrosis
#7
JOURNAL ARTICLE
Huiyul Park, Eileen L Yoon, Mimi Kim, Hye-Lin Kim, Mi Kyung Kim, Yu-Mi Kim, Dae Won Jun
Our study aimed to conduct a comparative evaluation of various noninvasive tests (NITs) for risk stratification in at-risk population for non-alcoholic fatty liver disease (NAFLD), focusing on cardiovascular and liver-related mortality. A total of 21,715 adults aged 40 years and older were enrolled at baseline. The mean follow-up period was 12.39 years. Three types of NITs (fibrosis-4 index [FIB-4], NAFLD fibrosis score [NFS], and steatosis-associated fibrosis estimator [SAFE] score) were used. When using the low cut-off as a 'rule-out' strategy, there were no significant differences in cardiovascular mortality between the 'rule-out' (low-risk) group and the 'rule-in' (intermediate- or high-risk) group based on FIB-4 (aHR = 1...
March 26, 2024: Scientific Reports
https://read.qxmd.com/read/38531378/new-nomenclature-for-nonalcoholic-fatty-liver-disease-understanding-metabolic-dysfunction-associated-steatotic-liver-disease-metabolic-dysfunction-and-alcohol-associated-liver-disease-and-their-implications-in-clinical-practice
#8
JOURNAL ARTICLE
Clémence M Canivet, Jérôme Boursier, Rohit Loomba
In June 2023, under the patronage of the American Association for Study of Liver Disease, the European Association for Study of the Liver, and the Asociación Latinoamericana para el Estudio del Hígado with the involvement of 236 participants from around the world, a new nomenclature and definition for nonalcoholic fatty liver disease (NAFLD) has been proposed. Metabolic dysfunction-associated steatotic liver disease (MASLD) was defined as presence of hepatic steatosis and at least one of the cardiometabolic risk factors with alcohol intake less than 140 g/wk for women and 210 g/wk for men and no other causes of steatosis...
March 26, 2024: Seminars in Liver Disease
https://read.qxmd.com/read/38531220/sesamin-alleviates-lipid-accumulation-induced-by-oleic-acid-via-pink1-parkin-mediated-mitophagy-in-hepg2-cells
#9
JOURNAL ARTICLE
Mengyun Dong, Tianliang Zhang, Xueli Liang, Xinyi Cheng, Fuyan Shi, Hang Yuan, Fengxiang Zhang, Qiqi Jiang, Xia Wang
Sesamin, a special compound present in sesame and sesame oil, has been reported a role in regulating lipid metabolism, while the underlying mechanisms remain unclear. Autophagy has been reported associated with lipid metabolism and regarded as a key modulator in liver steatosis. The present work aimed to investigate whether sesamin could exert its protective effects against lipid accumulation via modulating autophagy in HepG2 cells stimulated with oleic acid (OA). Cell viability was evaluated using the CCK-8 method, and triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein, cholesterol (LDL-C), alanine aminotransferase (ALT), along with aspartate aminotransferase (AST) were assessed by oil red O staining, transmission electron microscopy (TEM), and biochemical kits to investigate the lipid-lowering effects of sesamin...
March 22, 2024: Biochemical and Biophysical Research Communications
https://read.qxmd.com/read/38531168/effect-of-circadian-rhythm-change-on-gut-microbiota-and-the-development-of-nonalcoholic-fatty-liver-disease-in-mice
#10
JOURNAL ARTICLE
Dan Zhao, Xinxue Wang, Huiwei Liu, Mingli Su, Mengxia Sun, Liangshun Zhang, Hua Ye
BACKGROUND: This study was to investigate the effect and possible mechanism of circadian rhythm change on the development of nonalcoholic fatty liver disease (NAFLD) in mice. METHODS: A total of 80 male SPF-grade 4-week C57BL/6J mice were randomly divided into normal diet normal light/dark cycle (ND-LD) and high-fat diet all dark (HFD-DD) groups. Weight measurements were taken weekly, and after 24 weeks of intervention, 24 mice from both groups were randomly selected and analyzed...
February 29, 2024: Sleep Medicine
https://read.qxmd.com/read/38529852/parenteral-nutrition-emulsion-inhibits-cyp3a4-in-an-ipsc-derived-liver-organoids-testing-platform
#11
JOURNAL ARTICLE
Sean P Harrison, Saphira F Baumgarten, Maria E Chollet, Benedicte Stavik, Anindita Bhattacharya, Runar Almaas, Gareth J Sullivan
OBJECTIVES: Parenteral nutrition (PN) is used for patients of varying ages with intestinal failure to supplement calories. Premature newborns with low birth weight are at a high risk for developing PN associated liver disease (PNALD) including steatosis, cholestasis, and gallbladder sludge/stones. To optimize nutrition regimens, models are required to predict PNALD. METHODS: We have exploited induced pluripotent stem cell derived liver organoids to provide a testing platform for PNALD...
March 26, 2024: Journal of Pediatric Gastroenterology and Nutrition
https://read.qxmd.com/read/38527697/sirt1-harnessing-multiple-pathways-to-hinder-nafld
#12
REVIEW
Cheng Tian, Rongrong Huang, Ming Xiang
Non-alcoholic fatty liver disease (NAFLD) encompasses hepatic steatosis, non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma. It is the primary cause of chronic liver disorders, with a high prevalence but no approved treatment. Therefore, it is indispensable to find a trustworthy therapy for NAFLD. Recently, mounting evidence illustrates that Sirtuin 1 (SIRT1) is strongly associated with NAFLD. SIRT1 activation or overexpression attenuate NAFLD, while SIRT1 deficiency aggravates NAFLD...
March 23, 2024: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://read.qxmd.com/read/38527558/dapagliflozin-ameliorates-hepatic-steatosis-via-suppressing-lxr%C3%AE-mediated-synthesis-of-lipids-and-bile-acids
#13
JOURNAL ARTICLE
Zijie Jin, Ruotong Yin, Yan Yuan, Chen Zheng, Peng Zhang, Yalin Wang, Hongbo Weng
Nonalcoholic fatty liver disease (NAFLD) prevalence is rising globally with no pharmacotherapies approved. Hepatic steatosis is closely associated with progression and prognosis of NAFLD. Dapagliflozin, kind of sodium-glucose cotransporter 2 (SGLT2) inhibitor, was found to improve NAFLD in clinical trials, while the underlying mechanism remains poorly elucidated. Here, we reported that dapagliflozin effectively mitigated liver injury and relieved lipid metabolism disorders in vivo. Further investigation showed that dapagliflozin markedly suppressed Liver X Receptor α (LXRα)-mediated synthesis of de novo lipids and bile acids (BAs)...
March 23, 2024: Biochemical Pharmacology
https://read.qxmd.com/read/38526946/metabolic-dysfunction-associated-steatotic-liver-disease-related-hepatic-fibrosis-increases-risk-of-insulin-resistance-type-2-diabetes-and-chronic-kidney-disease
#14
JOURNAL ARTICLE
Weijing Zhang, Wen Jing Song, Weiyu Chen, Zoucheng Pan, Jiawei Zhang, Li Fan, Jie Li
Metabolic dysfunction-associated steatotic liver disease (MASLD) (previously called nonalcoholic fatty liver disease, NAFLD) is associated with cardiometabolic risk factors and chronic kidney disease (CKD). However, evidence is lacking regarding whether the severity of fibrosis is affected by these risk factors and diseases and to what degree. We aimed to determine the correlation between these factors and vibration-controlled transient elastography-determined liver stiffness measurements (LSMs) and controlled attenuation parameter (CAP) values in a sample of the US population...
March 22, 2024: European Journal of Gastroenterology & Hepatology
https://read.qxmd.com/read/38524631/anti-osteoporotic-treatments-in-the-era-of-non-alcoholic-fatty-liver-disease-friend-or-foe
#15
REVIEW
Maria Eleni Chondrogianni, Ioannis Kyrou, Theodoros Androutsakos, Christina-Maria Flessa, Evangelos Menenakos, Kamaljit Kaur Chatha, Yekaterina Aranan, Athanasios G Papavassiliou, Eva Kassi, Harpal S Randeva
Over the last years non-alcoholic fatty liver disease (NAFLD) has grown into the most common chronic liver disease globally, affecting 17-38% of the general population and 50-75% of patients with obesity and/or type 2 diabetes mellitus (T2DM). NAFLD encompasses a spectrum of chronic liver diseases, ranging from simple steatosis (non-alcoholic fatty liver, NAFL) and non-alcoholic steatohepatitis (NASH; or metabolic dysfunction-associated steatohepatitis, MASH) to fibrosis and cirrhosis with liver failure or/and hepatocellular carcinoma...
2024: Frontiers in Endocrinology
https://read.qxmd.com/read/38524129/expression-of-immune-related-genes-and-possible-regulatory-mechanisms-in-different-stages-of-non-alcoholic-fatty-liver-disease
#16
JOURNAL ARTICLE
Risheng He, Canghai Guan, Xudong Zhao, Liang Yu, Yunfu Cui
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD), which includes simple steatosis (SS) and non-alcoholic steatohepatitis (NASH), is a significant contributor to liver disease on a global scale. The change of immunity-related genes (IRGs) expression level leads to different immune infiltrations. However, the expression of IRGs and possible regulatory mechanisms involved in NAFLD remain unclear. The objective of our research is to investigate crucial genes linked to the development of NAFLD and the transition from SS to NASH...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38523737/17-beta-hydroxysteroid-dehydrogenase-13-loss-of-function-does-not-confer-protection-to-nonalcoholic-fatty-liver-disease-in-indian-population
#17
JOURNAL ARTICLE
Bale Govardhan, V Kulkarni Anand, Padaki Nagaraja Rao, P Balachandran Menon, Sharma Mithun, Mitnala Sasikala, T R Sowmya, Sekaran Anuradha, C Pawar Smita, D Nageshwar Reddy, Vishnubhotla Ravikanth
BACKGROUND: A splice variant in HSD17B13 gene is demonstrated to protect against nonalcoholic fatty liver disease (NAFLD), and mitigate the effect of Patatin-like phospholipase domain-containing 3 ( PNPLA3 -I148M). It is being explored as a putative drug target and in polygenic risk scores. Based on whole exome sequencing (WES) in our cohort of biopsy proven NAFLD and limited data on the variant in our ethnicity, we sought to explore its role. METHODS: This is a cross-sectional study that recruited 1,020 individuals with ultrasound/biopsy-confirmed NAFLD and matched controls...
2024: Journal of Clinical and Experimental Hepatology
https://read.qxmd.com/read/38522486/derlin-1-promotes-diet-induced-non-alcoholic-fatty-liver-disease-via-increasing-ripk3-mediated-necroptosis
#18
JOURNAL ARTICLE
Ting Wang, Dehua Wang, Ge Kuang, Xia Gong, Li Zhang, Jingyuan Wan, Ke Li
BACKGROUND & AIMS: Unrestricted endoplasmic reticulum (ER) stress and the continuous activation of ER associated protein degradation (ERAD) pathway might lead to the aggravation of non-alcoholic steatohepatitis (NASH). Derlin-1 has been considered to be an integral part of the ERAD pathway, which is involved in the regulation of the transport and excretion of protein degradation products within ER. However, the regulatory role and mechanism of Derlin-1 in NASH remains unclear. METHODS: The expression of Derlin-1 was firstly detected in the liver of normal and NASH animal model and patient...
March 22, 2024: Free Radical Biology & Medicine
https://read.qxmd.com/read/38522397/interoperator-reproducibility-of-quantitative-ultrasound-analysis-of-hepatic-steatosis-in-participants-with-suspected-masld-a-prospective-study
#19
JOURNAL ARTICLE
Haohao Yin, Bing Xiong, Jifeng Yu, Yunling Fan, Boyang Zhou, Yikang Sun, Lifan Wang, Huixiong Xu, Yuli Zhu
OBJECTIVES: To evaluate the reproducibility of tissue attenuation imaging (TAI) and tissue scatter distribution imaging (TSI) measurements in adults with suspected metabolic dysfunction-associated steatotic liver disease (MASLD) between radiologists with varying experience. MATERIALS AND METHODS: Participants with suspected MASLD were prospectively recruited. TAI and TSI were performed for each participant by two radiologists with different levels of experience...
March 16, 2024: European Journal of Radiology
https://read.qxmd.com/read/38522165/metabolic-dysfunction-associated-steatotic-liver-disease-an-opportunity-for-collaboration-between-cardiology-and-hepatology
#20
REVIEW
Paolo Raggi, Jovana Milic, Marcella Manicardi, Felice Cinque, Mark G Swain, Giada Sebastiani, Giovanni Guaraldi
Altered metabolic function has many detrimental effects on the body that can manifest as cardiovascular and liver diseases. Traditional approaches to understanding and treating metabolic dysfunction-associated disorders have been organ-centered, leading to silo-type disease care. However, given the broad impact that systemic metabolic dysfunction has on the human body, approaches that simultaneously involve multiple medical specialists need to be developed and encouraged to optimize patient outcomes. In this review, we highlight how several of the treatments developed for cardiac care may have a beneficial effect on the liver and vice versa, suggesting that there is a need to target the disease process, rather than specifically target the cardiovascular or liver specific sequelae of metabolic dysfunction...
March 16, 2024: Atherosclerosis
keyword
keyword
50860
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.